Abstract 922: Preclinical anticancer activity of LSZ102, a novel oral selective estrogen receptor degrader targeting wild-type and mutant ER

Authors: L. Alex Gaither, Choi Lai Tiong Yip, Chunrong Wang, Weiyi Toy, Qing Sheng, Jinyun Chen, Yuji Mishina, Rita Das, Stefan Peukert, Alice Loo, Sarat Chandarlapaty, Adam Crystal, Tinya J. Abrams

Published: 2019-08-07

DOI: 10.1158/1538-7445.am2019-922

Source: Full article